Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon and keeping the price target at $235.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Cherny has given his Buy rating due to a combination of factors including the stability expected from the CEO transition at Icon. The appointment of Barry Balfe, who has over two decades of experience with the company, is seen as a positive move. His extensive knowledge across various roles within the organization is anticipated to be beneficial as Icon continues to navigate a challenging market environment and establish partnerships with major pharmaceutical companies.
Despite recent operational hurdles, such as higher-than-average cancellations linked to specific trials, Cherny believes that Icon has managed these uncertainties effectively. The current market conditions have led to Icon’s shares being undervalued relative to their intrinsic worth, and as the market improves, the company is expected to be in a strong position. Therefore, the CEO transition is not expected to alter the company’s positive trajectory, reinforcing the Buy rating.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.